Kodiak Sciences

Kodiak Sciences is a public biopharmaceutical company founded in 2009 and headquartered in Palo Alto, California. The company completed its initial public offering on NASDAQ in 2019. Kodiak develops biologic therapies targeting retinal diseases, particularly macular degeneration and other conditions affecting the back of the eye. The company focuses on addresses conditions with limited or no current treatment options, pursuing clinical development programs for biologics in ophthalmology. As a public biotech company in clinical and preclinical stages, Kodiak offers opportunities for scientists and clinicians to work on therapies that could restore or preserve vision in patients with serious retinal conditions.